(re goe RAF e nib)
- BAY 73-4506
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Stivarga: 40 mg [contains soybean lecithin]
Brand Names: U.S.
- Antineoplastic Agent, Tyrosine Kinase Inhibitor
- Antineoplastic Agent, Vascular Endothelial Growth Factor (VEGF) Inhibitor
Regorafenib is a multikinase inhibitor; it targets kinases involved with tumor angiogenesis, oncogenesis, and maintenance of the tumor microenvironment which results in inhibition of tumor growth. Specifically, it inhibits VEGF receptors 1-3, KIT, PDGFR-alpha, PDGFR-beta, RET, FGFR1 and 2, TIE2, DDR2, TrkA, Eph2A, RAF-1. BRAF, BRAFV600E, SAPK2, PTK5, and Abl.
A high-fat meal increased the mean AUC of the parent drug by 48% compared to the fasted state and decreased the mean AUC of the M-2 (N-oxide) and M-5 (N-oxide and N-desmethyl) active metabolites by 20% and 51%, respectively. A low-fat meal increased the mean AUC of regorafenib, M-2, and M-5 by 36%, 40% and 23%, respectively (as compared to the fasted state).
Hepatic via CYP3A4 and UGT1A9, primarily to active metabolites M-2 (N-oxide) and M-5 (N-oxide and N-desmethyl)
Feces (71%; 47% as parent compound; 24% as metabolites); Urine (19%)
Time to Peak
Regorafenib: 28 hours (range: 14 to 58 hours); M-2 metabolite: 25 hours (range: 14 to 32 hours); M-5 metabolite: 51 hours (range: 32 to 70 hours)
99.5% (active metabolites M-2 and M-5 are also highly protein bound)
Use: Labeled Indications
Colorectal cancer, metastatic: Treatment of metastatic colorectal cancer in patients previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, anti-VEGF therapy, and anti-EGFR therapy (if RAS wild type)
Gastrointestinal stromal tumors: Treatment of locally-advanced, unresectable, or metastatic gastrointestinal stromal tumor (GIST) in patients previously treated with imatinib and sunitinib
There are no contraindications listed in the manufacturer’s US labeling.
Canadian labeling: Hypersensitivity to regorafenib, any component of the formulation, or sorafenib.
Colorectal cancer, metastatic: Oral: 160 mg once daily for the first 21 days of each 28-day cycle; continue until disease progression or unacceptable toxicity (Grothey, 2013)
Gastrointestinal stromal tumor (GIST), locally-advanced, unresectable, or metastatic: Oral: 160 mg once daily for the first 21 days of each 28-day cycle; continue until disease progression or unacceptable toxicity (Demetri, 2013)
Missed doses: Do not administer 2 doses on the same day to make up for a missed dose from the previous day.
Hepatocellular carcinoma, intermediate or advanced (off-label use): Oral: 160 mg once daily on days 1 to 21 of a 28-day cycle; continue until disease progression or unacceptable toxicity (Bruix 2016)
Refer to adult dosing.
Dosing: Renal Impairment
CrCl 60 to 89 mL/minute: No dosage adjustment necessary.
CrCl 30 to 59 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (limited pharmacokinetic data available).
CrCl <30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).
Dosing: Hepatic Impairment
Preexisting mild or moderate impairment (Child-Pugh Class A or B): No dosage adjustment necessary; closely monitor for adverse effects.
Preexisting severe impairment (Child-Pugh Class C): Use is not recommended (has not been studied).
Hepatotoxicity during treatment:
Grade 3 AST and/or ALT elevation: Withhold dose until recovery. If benefit of treatment outweighs toxicity risk, resume therapy at a reduced dose of 120 mg once daily.
AST or ALT >20 times ULN: Discontinue permanently.
AST or ALT >3 times ULN and bilirubin >2 times ULN: Discontinue permanently.
Recurrence of AST or ALT >5 times ULN despite dose reduction to 120 mg: Discontinue permanently.
Dosing: Adjustment for Toxicity
Grade 2 hand-foot skin reaction (HFSR; palmar-plantar erythrodysesthesia [PPE]) of any duration: Reduce dose to 120 mg once daily for first occurrence. If grade 2 HFSR recurs at this dose, further reduce the dose to 80 mg once daily. Interrupt therapy for grade 2 HFSR that is recurrent or fails to improve within 7 days in spite of dosage reduction.
Grade 3 HFSR: Interrupt therapy for a minimum of 7 days. Upon recovery, reduce dose to 120 mg once daily. If grade 2 to 3 toxicity recurs at this dose, further reduce dose to 80 mg once daily upon recovery. Interrupt therapy for grade 2 to 3 HFSR that is recurrent or fails to improve within 7 days in spite of dosage reduction.
Recurrent or persistent HFSR at 80 mg once daily: Discontinue treatment.
Other dermatologic toxicity: Withhold treatment, reduce dose or permanently discontinue treatment depending on the severity and persistence of the dermatologic toxicity. Symptomatic relief may be managed with supportive measures.
Hypertension: Grade 2 (symptomatic): Interrupt therapy.
Other toxicity: Any grade 3 or 4 adverse reaction (other than hepatotoxicity): Interrupt therapy; upon recovery, reduce dose to 120 mg once daily. If any grade 3 or 4 adverse reaction occurs while on this reduced dose, may further reduce dose to 80 mg once daily upon recovery. For any grade 4 adverse reaction, only resume therapy if the benefit outweighs the risk. Permanently discontinue therapy if unable to tolerate 80 mg once daily.
Gastrointestinal perforation/fistula: Discontinue permanently.
Hemorrhage (severe or life-threatening): Discontinue permanently.
Reversible posterior leukoencephalopathy syndrome (RPLS): Discontinue.
Wound dehiscence: Discontinue.
Oral: Take at the same time each day. Swallow tablet whole with water after a low-fat meal (containing <600 calories and <30% fat). Hazardous agent; use appropriate precautions for handling and disposal (meets NIOSH 2014 criteria).
Avoid grapefruit juice.
Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Store tablets in the original bottle and protect from moisture (do not remove the desiccant); keep container tightly closed. Discard any unused tablets 7 weeks after opening the bottle.
Aprepitant: May increase the serum concentration of CYP3A4 Substrates. Monitor therapy
BCRP/ABCG2 Substrates: Regorafenib may increase the serum concentration of BCRP/ABCG2 Substrates. Monitor therapy
Beta-Blockers: Regorafenib may enhance the bradycardic effect of Beta-Blockers. Monitor therapy
Bisphosphonate Derivatives: Systemic Angiogenesis Inhibitors may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Specifically, the risk for osteonecrosis of the jaw may be increased. Monitor therapy
Bosentan: May decrease the serum concentration of CYP3A4 Substrates. Monitor therapy
Calcium Channel Blockers (Nondihydropyridine): Regorafenib may enhance the bradycardic effect of Calcium Channel Blockers (Nondihydropyridine). Monitor therapy
Conivaptan: May increase the serum concentration of CYP3A4 Substrates. Avoid combination
CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates. Monitor therapy
CYP3A4 Inducers (Strong): May decrease the serum concentration of Regorafenib. Avoid combination
CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates. Monitor therapy
CYP3A4 Inhibitors (Strong): May increase the serum concentration of Regorafenib. Avoid combination
Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates. Management: Seek alternatives to the CYP3A4 substrate when possible. If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects). Consider therapy modification
Dasatinib: May increase the serum concentration of CYP3A4 Substrates. Monitor therapy
Deferasirox: May decrease the serum concentration of CYP3A4 Substrates. Monitor therapy
Digoxin: Regorafenib may enhance the bradycardic effect of Digoxin. Monitor therapy
Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates. Monitor therapy
Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates. Avoid combination
Grapefruit Juice: May increase the serum concentration of Regorafenib. Avoid combination
Idelalisib: May increase the serum concentration of CYP3A4 Substrates. Avoid combination
Irinotecan Products: UGT1A1 Inhibitors may increase serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, concentrations of SN-38 may be increased. UGT1A1 Inhibitors may increase the serum concentration of Irinotecan Products. Avoid combination
Ivabradine: Regorafenib may enhance the bradycardic effect of Ivabradine. Monitor therapy
Ivacaftor: May increase the serum concentration of CYP3A4 Substrates. Monitor therapy
Luliconazole: May increase the serum concentration of CYP3A4 Substrates. Monitor therapy
Neomycin: May decrease serum concentrations of the active metabolite(s) of Regorafenib. Monitor therapy
Netupitant: May increase the serum concentration of CYP3A4 Substrates. Monitor therapy
Palbociclib: May increase the serum concentration of CYP3A4 Substrates. Monitor therapy
PAZOPanib: BCRP/ABCG2 Inhibitors may increase the serum concentration of PAZOPanib. Avoid combination
Siltuximab: May decrease the serum concentration of CYP3A4 Substrates. Monitor therapy
Simeprevir: May increase the serum concentration of CYP3A4 Substrates. Monitor therapy
St John's Wort: May decrease the serum concentration of Regorafenib. Avoid combination
Stiripentol: May increase the serum concentration of CYP3A4 Substrates. Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity. Any CYP3A4 substrate used with stiripentol requires closer monitoring. Consider therapy modification
Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates. Monitor therapy
Topotecan: BCRP/ABCG2 Inhibitors may increase the serum concentration of Topotecan. Consider therapy modification
Warfarin: May enhance the adverse/toxic effect of Regorafenib. Specifically, the risk for bleeding may be increased. Monitor therapy
Cardiovascular: Hypertension (30% to 59%; grade ≥3: 8% to 28%)
Central nervous system: Fatigue (52% to 64%), voice disorder (30% to 39%), pain (29%), headache (10% to 16%)
Dermatologic: Palmar-plantar erythrodysesthesia (45% to 67%; grade ≥3: 17% to 22%), skin rash (26% to 30%; grade ≥3: 6% to 7%), alopecia (24%)
Endocrine & metabolic: Hypocalcemia (17% to 59%), hypophosphatemia (55% to 57%), weight loss (14% to 32%), hyponatremia (30%), increased amylase (26%), hypokalemia (21% to 26%), hypothyroidism (18%)
Gastrointestinal: Diarrhea (43% to 47%), decreased appetite (31% to 47%), increased serum lipase (14% to 46%), mucositis (33% to 40%), nausea (20%), vomiting (17%)
Hematologic & oncologic: Anemia (79%; grade 3: 5%; grade 4: 1%), lymphocytopenia (30% to 54%; grade 3: 8% to 9%), thrombocytopenia (13% to 41%; grade 3: 1% to 2%; grade 4: <1%), increased INR (24%), hemorrhage (11% to 21%; grade ≥3: 2% to 4%), neutropenia (3% to 16%; grade 3: 1%)
Hepatic: Increased serum AST (58% to 65%; grade 3: 5%; grade 4: 1%), increased serum ALT (45%; grade 3: 4% to 5%; grade 4: 1%), hyperbilirubinemia (33% to 45%)
Infection: Infection (31% to 32%; grade ≥3: 5% to 9%)
Neuromuscular & skeletal: Stiffness (14%)
Renal: Proteinuria (33% to 60%)
Miscellaneous: Fever (21% to 28%)
1% to 10%:
Cardiovascular: Ischemic heart disease (≤1%), myocardial infarction (≤1%)
Gastrointestinal: Gastrointestinal fistula (≤2%), gastrointestinal perforation (≤2%)
Hepatic: Hepatic failure (≤2%)
<1% (Limited to important or life-threatening): Erythema multiforme, hepatic injury (severe), hypersensitivity reaction, hypertensive crisis, keratoacanthoma, reversible posterior leukoencephalopathy syndrome, squamous cell carcinoma of skin, Stevens-Johnson syndrome, toxic epidermal necrolysis
Concerns related to adverse effects:
• Cardiovascular events: Myocardial ischemia and infarction were observed at a higher incidence than placebo in a clinical trial. Interrupt therapy in patients who develop new or acute onset ischemia or infarction; resume only if the benefit of therapy outweighs the cardiovascular risk.
• Dermatologic toxicity: Hand-foot skin reaction (HFSR), also known as palmar-plantar erythrodysesthesia (PPE), and rash were commonly seen in clinical trials; erythema multiforme and Stevens Johnson syndrome were also observed more frequently in regorafenib-treated patients. Toxic epidermal necrolysis occurred rarely. Onset of dermatologic toxicity typically occurs in the first cycle of treatment. Therapy interruptions, dosage reductions, and/or discontinuation may be necessary depending on the severity and persistence. Supportive treatment may be of benefit for symptomatic relief. Pooled data from several clinical trials showed a higher incidence of HFSR in Asian patients compared to Caucasians.
In addition to recommended dosage modifications, the following treatments may be used for management of HFSR (McLellan 2015): A manicure/pedicure to remove hyperkeratotic areas/calluses which may predispose to HFSR and mechanical support/correction for abnormal weight bearing prior to treatment are recommended. During treatment, patients should use alcohol-free moisturizers liberally, reduce exposure to hot water (may exacerbate hand-foot symptoms), avoid constrictive footwear and excessive skin friction, and avoid vigorous exercise/activities that may stress hands or feet. Patients should wear thick cotton gloves/socks and wear shoes with padded insoles. Grade 1 HFSR may be relieved with moisturizing creams, cotton gloves and socks (at night) and/or keratolytic creams such as urea (10% to 40%) or salicylic acid (6%) along with a topical analgesic (eg, lidocaine gel) to relieve pain. Apply topical steroid (eg, clobetasol ointment or foam) twice daily to erythematous areas of grade 2 HFSR (in addition to continuing grade 1 management); topical analgesics and then systemic analgesics (if appropriate) may be used for pain control; dose reduction may be necessary. Grade 3 HFSR should be managed by continuing grades 1 and 2 symptomatic management and interrupting treatment for at least 7 days until resolved to grade 1 or lower.
• Gastrointestinal perforation: Gastrointestinal perforation or fistula has occurred in a small number of patients treated with regorafenib; some cases were fatal. Monitor for signs/symptoms of perforation (fever, abdominal pain with constipation, and/or nausea/vomiting); permanently discontinue if perforation or fistula develop.
• Hemorrhage: The incidence of hemorrhage was increased with regorafenib. Hemorrhage of the respiratory, gastrointestinal, or genitourinary tracts was observed in trials; some cases were fatal. Permanently discontinue in patients who experience severe or life-threatening bleeding. In patients receiving concomitant warfarin, monitor INR frequently.
• Hepatotoxicity: [US Boxed Warning]: Severe and sometimes fatal hepatotoxicity has been observed in clinical trials. Monitor hepatic function at baseline and during treatment. Interrupt therapy for hepatotoxicity; dose reductions or discontinuation are necessary depending on the severity and persistence. Hepatic dysfunction, characterized by a hepatocellular injury pattern, typically occurred with the first 2 months of treatment in clinical trials. Closely monitor in patients with mild or moderate impairment for adverse events; use is not recommended in severe impairment. A higher incidence of hepatotoxicity has been observed in Asian patients (particularly Japanese), compared to Caucasians (Li 2015).
• Hypersensitivity: Hypersensitivity reactions have been observed with regorafenib.
• Hypertension: Elevated blood pressure was observed in clinical trials (onset typically in the first cycle of therapy); ensure blood pressure is adequately controlled prior to initiation. Monitor blood pressure weekly for the first 6 weeks and monthly thereafter or as clinically indicated; if hypertension develops, interrupt therapy or permanently discontinue for severe or uncontrolled hypertension. Hypertensive crisis has occurred in some patients.
• Reversible posterior leukoencephalopathy syndrome (RPLS): RPLS occurred very rarely in regorafenib-treated patients; evaluate promptly if symptoms (eg, seizures, severe headache, visual disturbances, confusion or altered mental function) occur. Discontinue if diagnosis is confirmed.
• Wound healing impairment: Regorafenib inhibits vascular endothelial growth factor, which may lead to impaired wound healing. Discontinue regorafenib at least 2 weeks prior to scheduled surgery; resume regorafenib postsurgery based on clinical judgment of wound healing; discontinue if wound dehiscence occurs.
Concurrent drug therapy issues:
• Drug-drug/drug-food interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.
• Asian patients: A higher incidence of hepatotoxicity and hand-foot skin reactions were observed in Asian patients, particularly in Japanese patients, compared to non-Asian patients (Li 2015).
• Hazardous agent: Use appropriate precautions for handling and disposal (meets NIOSH 2014 criteria).
Obtain liver function tests at baseline, every 2 weeks during the first 2 months of treatment, then monthly or more frequently if clinically necessary (weekly until improvement if liver function tests are elevated). CBC with differential and platelets and serum electrolytes (baseline and periodic). Monitor INR more frequently if receiving warfarin. Monitor blood pressure weekly for the first 6 weeks of therapy and with every subsequent cycle, or more frequently if indicated. Monitor for hand-foot skin reaction (HFSR)/palmar-plantar erythrodysesthesia (PPE); it is recommended to monitor for signs of HFSR during the first weeks of treatment, then every 1 to 2 weeks for 2 cycles, then every 4 to 6 weeks thereafter (McLellan 2015). Monitor for signs/symptoms of cardiac ischemia or infarction, bleeding, GI perforation or fistula, and reversible posterior leukoencephalopathy syndrome (severe headaches, seizure, confusion, or change in vision). Monitor for impaired wound healing.
In animal reproduction studies, teratogenic effects were observed with doses less than the equivalent human dose. Based on animal reproduction studies and the mechanism of action, regorafenib may cause fetal harm if administered during pregnancy. Patients (male and female) should use effective contraception during therapy and for at least 2 months following treatment.
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Patient may experience weight loss, lack of appetite, mouth irritation, change in voice, muscle rigidity, or hair loss. Have patient report immediately to prescriber signs of liver problems (dark urine, fatigue, lack of appetite, nausea, abdominal pain, light-colored stools, vomiting, or jaundice), signs of posterior reversible encephalopathy syndrome (confusion, not alert, vision changes, seizures, or severe headache), signs of bleeding (vomiting blood or vomit that looks like coffee grounds; coughing up blood; hematuria; black, red, or tarry stools; bleeding from the gums; abnormal vaginal bleeding; bruises without a reason or that get bigger; or any severe or persistent bleeding), signs of infection, signs of fluid and electrolyte problems (mood changes, confusion, muscle pain or weakness, abnormal heartbeat, severe dizziness or passing out, tachycardia, increased thirst, seizures, loss of strength and energy, lack of appetite, urinary retention or change in amount of urine passed, dry mouth, dry eyes, or nausea or vomiting), severe headache, vision changes, redness or irritation of palms or soles of feet, severe dizziness, passing out, angina, shortness of breath, nausea, vomiting, severe loss of strength and energy, wound healing impairment, severe abdominal pain, abdominal edema, severe diarrhea, or signs of Stevens-Johnson syndrome/toxic epidermal necrolysis (red, swollen, blistered, or peeling skin [with or without fever]; red or irritated eyes; or sores in mouth, throat, nose, or eyes) (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for healthcare professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience and judgment in diagnosing, treating and advising patients.
More about regorafenib
- Other brands: Stivarga